<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426763</url>
  </required_header>
  <id_info>
    <org_study_id>0624-204</org_study_id>
    <secondary_id>SPD616-204</secondary_id>
    <nct_id>NCT01426763</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase</brief_title>
  <official_title>An Open-label Multiple-dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to:&#xD;
&#xD;
        1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with&#xD;
           recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE)&#xD;
           who previously participated in CINRYZE Study 0624-200 (NCT01095497)&#xD;
&#xD;
        2. Characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered&#xD;
           CINRYZE with rHuPH20&#xD;
&#xD;
        3. Assess the immunogenicity of CINRYZE following subcutaneous (SC) administration of&#xD;
           CINRYZE with rHuPH20&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2011</start_date>
  <completion_date type="Actual">November 28, 2011</completion_date>
  <primary_completion_date type="Actual">November 28, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study</measure>
    <time_frame>18 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change C1 Inhibitor (C1INH)</measure>
    <time_frame>18 days</time_frame>
    <description>Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change C4 Compliment</measure>
    <time_frame>18 days</time_frame>
    <description>Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With C1 INH Antibodies</measure>
    <time_frame>Day 1 (pre-dose), Day 18 (168 h post Dose 4), and 30 (±2) days after the last dose of study drug (Dose 4)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>SC CINRYZE with rHuPH20 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC CINRYZE with rHuPH20 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CINRYZE with rHuPH20</intervention_name>
    <arm_group_label>SC CINRYZE with rHuPH20 Dose Level 1</arm_group_label>
    <arm_group_label>SC CINRYZE with rHuPH20 Dose Level 2</arm_group_label>
    <other_name>C1 esterase inhibitor (human)</other_name>
    <other_name>Recombinant human hyaluronidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for this protocol, a subject must:&#xD;
&#xD;
          1. Provide informed consent/assent, as appropriate.&#xD;
&#xD;
          2. Have previously participated in CINRYZE Study 0624-200 and completed the subcutaneous&#xD;
             therapy period in that study.&#xD;
&#xD;
          3. During the 3 consecutive months prior to screening, have a history of less than 1 HAE&#xD;
             attack per month (average) that required treatment with C1 INH therapy or other blood&#xD;
             products.&#xD;
&#xD;
          4. Agree to avoid his/her known HAE triggers during the study to the best of his/her&#xD;
             ability.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To be eligible for this protocol, a subject must not:&#xD;
&#xD;
          1. Have received C1 INH therapy or any blood products for treatment or prevention of an&#xD;
             HAE attack within 14 days prior to the first dose of study drug.&#xD;
&#xD;
          2. Have received any ecallantide (Kalbitor), icatibant (Firazyr), or antifibrinolytics&#xD;
             (e.g., tranexamic acid) within 14 days prior to the first dose of study drug.&#xD;
&#xD;
          3. Have any change (start, stop, or change in dose) in androgen therapy (e.g., danazol,&#xD;
             oxandrolone, stanozolol, testosterone) within 14 days prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          4. If female, have started taking or changed the dose of any hormonal contraceptive&#xD;
             regimen or hormone replacement therapy (i.e., estrogen/progestin containing products)&#xD;
             within 3 months prior to the first dose of study drug.&#xD;
&#xD;
          5. Have a history of abnormal blood clotting.&#xD;
&#xD;
          6. Have a history of allergic reaction to products containing C1 INH or other blood&#xD;
             products.&#xD;
&#xD;
          7. Have a known allergy to hyaluronidase or any other ingredient in rHuPH20.&#xD;
&#xD;
          8. Be pregnant or breastfeeding.&#xD;
&#xD;
          9. Have received an investigational study drug within 30 days prior to the first dose of&#xD;
             study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ViroPharma Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <results_first_submitted>November 30, 2012</results_first_submitted>
  <results_first_submitted_qc>November 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2013</results_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>C1 esterase inhibitor</keyword>
  <keyword>C1 INH</keyword>
  <keyword>Subcutaneous</keyword>
  <keyword>hyaluronidase</keyword>
  <keyword>rHuPH20</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement C1s</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1</title>
          <description>SC injection of 1000 Units of CINRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
        <group group_id="P2">
          <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
          <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1</title>
          <description>SC injection of 1000 Units of CINRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
        <group group_id="B2">
          <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
          <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.5" spread="7.79"/>
                    <measurement group_id="B2" value="33.7" spread="10.27"/>
                    <measurement group_id="B3" value="32.6" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study</title>
        <time_frame>18 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1</title>
            <description>SC injection of 1000 Units of CINRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
          <group group_id="O2">
            <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
            <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants with injection site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who discontinued study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants who withdrew from the study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change C1 Inhibitor (C1INH)</title>
        <description>Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
        <time_frame>18 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1</title>
            <description>1000 Units of SC CYNRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
          <group group_id="O2">
            <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
            <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change C1 Inhibitor (C1INH)</title>
          <description>Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
          <population>Intent to Treat</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Hour (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0248" spread="0.0565"/>
                    <measurement group_id="O2" value="0.00483" spread="0.00904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour (h) post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0273" spread="0.065"/>
                    <measurement group_id="O2" value="0.00383" spread="0.00417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0302" spread="0.0637"/>
                    <measurement group_id="O2" value="0.008" spread="0.0123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0275" spread="0.0602"/>
                    <measurement group_id="O2" value="0.0095" spread="0.00729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0382" spread="0.0652"/>
                    <measurement group_id="O2" value="0.011" spread="0.00537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0398" spread="0.0599"/>
                    <measurement group_id="O2" value="0.020" spread="0.00678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0455" spread="0.0624"/>
                    <measurement group_id="O2" value="0.031" spread="0.0154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0625" spread="0.0728"/>
                    <measurement group_id="O2" value="0.0612" spread="0.0212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0665" spread="0.0749"/>
                    <measurement group_id="O2" value="0.0603" spread="0.0213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0243" spread="0.0234"/>
                    <measurement group_id="O2" value="0.0507" spread="0.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0387" spread="0.0749"/>
                    <measurement group_id="O2" value="0.00833" spread="0.00852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.00883"/>
                    <measurement group_id="O2" value="0.0388" spread="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0288" spread="0.0644"/>
                    <measurement group_id="O2" value="0.00833" spread="0.0095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00217" spread="0.00271"/>
                    <measurement group_id="O2" value="0.004" spread="0.00405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.0119"/>
                    <measurement group_id="O2" value="0.0128" spread="0.00854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0193" spread="0.012"/>
                    <measurement group_id="O2" value="0.033" spread="0.0196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0233" spread="0.0126"/>
                    <measurement group_id="O2" value="0.0377" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0238" spread="0.012"/>
                    <measurement group_id="O2" value="0.0333" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0257" spread="0.0142"/>
                    <measurement group_id="O2" value="0.037" spread="0.0215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0298" spread="0.0124"/>
                    <measurement group_id="O2" value="0.039" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0354" spread="0.0118"/>
                    <measurement group_id="O2" value="0.0397" spread="0.0157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0347" spread="0.018"/>
                    <measurement group_id="O2" value="0.0623" spread="0.0207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0273" spread="0.0171"/>
                    <measurement group_id="O2" value="0.0562" spread="0.00906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0167" spread="0.0185"/>
                    <measurement group_id="O2" value="0.046" spread="0.0106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0165" spread="0.0214"/>
                    <measurement group_id="O2" value="0.0157" spread="0.00797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00933" spread="0.0201"/>
                    <measurement group_id="O2" value="0.0382" spread="0.0935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change C4 Compliment</title>
        <description>Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
        <time_frame>18 days</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1</title>
            <description>1000 Units of SC CYNRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
          <group group_id="O2">
            <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
            <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change C4 Compliment</title>
          <description>Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.</description>
          <population>Intent to Treat</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Hour (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.00" spread="15.4"/>
                    <measurement group_id="O2" value="13.3" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour (h) post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="14.3"/>
                    <measurement group_id="O2" value="10.3" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="13.8"/>
                    <measurement group_id="O2" value="11.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="11.7"/>
                    <measurement group_id="O2" value="11.5" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="13.6"/>
                    <measurement group_id="O2" value="13.2" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="14.2"/>
                    <measurement group_id="O2" value="14.0" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="16.6"/>
                    <measurement group_id="O2" value="22.5" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="15.6"/>
                    <measurement group_id="O2" value="30.5" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="23.1"/>
                    <measurement group_id="O2" value="49.8" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" spread="14.5"/>
                    <measurement group_id="O2" value="53.3" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" spread="21.6"/>
                    <measurement group_id="O2" value="53.2" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h post Dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6" spread="22.6"/>
                    <measurement group_id="O2" value="70.8" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" spread="19.1"/>
                    <measurement group_id="O2" value="66.3" spread="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="18.7"/>
                    <measurement group_id="O2" value="69.3" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="18.4"/>
                    <measurement group_id="O2" value="62.5" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="18.8"/>
                    <measurement group_id="O2" value="57.3" spread="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="24.5"/>
                    <measurement group_id="O2" value="59.7" spread="52.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="17.9"/>
                    <measurement group_id="O2" value="53.3" spread="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="22.9"/>
                    <measurement group_id="O2" value="63.3" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="21.6"/>
                    <measurement group_id="O2" value="59.7" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="20.3"/>
                    <measurement group_id="O2" value="56.5" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="23.0"/>
                    <measurement group_id="O2" value="64.7" spread="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="22.4"/>
                    <measurement group_id="O2" value="65.7" spread="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="20.6"/>
                    <measurement group_id="O2" value="72.2" spread="57.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="15.5"/>
                    <measurement group_id="O2" value="58.7" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 h post Dose 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="18.4"/>
                    <measurement group_id="O2" value="44.8" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With C1 INH Antibodies</title>
        <time_frame>Day 1 (pre-dose), Day 18 (168 h post Dose 4), and 30 (±2) days after the last dose of study drug (Dose 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1</title>
            <description>SC injection of 1000 Units of CINRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
          <group group_id="O2">
            <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
            <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With C1 INH Antibodies</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (pre-dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 18 (168 h post Dose 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 (±2) days after the last dose of study drug (Dose 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1</title>
          <description>SC injection of 1000 Units of CINRYZE with ~20,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
        <group group_id="E2">
          <title>SC CINRYZE With rHuPH20 Dose Level 2</title>
          <description>SC injection of 2000 Units of CINRYZE with ~40,000 Units of rHuPH20 twice weekly for two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <description>Two subjects (one at each dose level) each reported two events of severe injection site erythema; all other adverse events reported in the study were of mild or moderate intensity.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Clinical Study Agreement. Most restrictive provision - PI will not publish results until after first of: multicenter publication is published or 24 months from study end. Thereafter, PI may publish his results. PI must provide copy of proposed publication to Sponsor for pre-review. If Sponsor requests, PI must delete Sponsor confidential information before publication and/or delay publication for 60 days so Sponsor can file for patents or take other action to protect its patent rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

